This site is intended for UK patients who have been prescribed NEXPOVIO®▼(selinexor). If you are a UK HCP, please click here.
▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information.
You can help by reporting any side effects you may get. See www.mhra.gov.uk/yellowcard for how to report side effects.

INFORMATION AND SUPPORT

for people who have been prescribed NEXPOVIO® to treat relapsed/refractory multiple myeloma


If you would like to get advice on managing your condition or learn more about NEXPOVIO®, including possible side effects and how to manage them, there are dedicated resources available for you to view or download below.

Additional support

Living with multiple myeloma may sometimes feel difficult to manage. However, there is support available to help you and your family. If you feel that you need additional support during your treatment, there are a number of patient organisations you can access, which provide valuable resources and opportunities to connect with people going through a similar experience. Examples of these organisations include:

Myeloma UK:

www.myeloma.org.uk

Blood Cancer UK:

www.bloodcancer.org.uk

Macmillan Cancer Support:

www.macmillan.org.uk


Keep note of how you are feeling about your treatment. It is important to remember that you are not alone and that your healthcare team is on hand to help you with any concerns about possible side effects, your condition or your treatment and to help make the best choices for your health.


MoA, mechanism of action.

Reference
NEXPOVIO® (selinexor). Summary of Product Characteristics. Menarini Stemline UK. 2024.

Reporting of side effects.
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard. By reporting side effects, you can help provide more information on the safety of this medicine.

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See www.mhra.gov.uk/yellowcard for how to report side effects.